Treatment and Outcome of Merkel Cell Carcinoma in A Single Center
10.3971/j.issn.1000-8578.2023.22.1101
- VernacularTitle:Merkel细胞癌单中心治疗及转归
- Author:
Mengwei REN
1
;
Xuemin XUE
;
Peng LIU
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang 065001, China
- Publication Type:Research Article
- Keywords:
Merkel cell carcinoma;
Cutaneous neuroendocrine carcinoma;
Surgery;
Radiotherapy;
Chemotherapy;
Immune checkpoint inhibitors
- From:
Cancer Research on Prevention and Treatment
2023;50(4):364-369
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical features, treatment, and outcome characteristics of patients with Merkel cell carcinoma. Methods The clinical manifestations, laboratory tests, diagnosis and treatment, and follow-up data of six patients with Merkel cell carcinoma were retrospectively analyzed. Results Among the six patients with Merkel cell carcinoma, four were males and two were females, with a median age of 66 years old (57-76 years old). All six patients presented with skin swelling, and the clinical stages were as follows: stageⅠ in three patients, stage Ⅲ in one patient, and stage IV in two patients. Two patients were treated with surgery alone, three patients with surgery combined with radiotherapy and/or chemotherapy, and one patient with immunotherapy combined with chemotherapy. Until the follow-up time, four patients had no disease progression, one patient died because of disease progression, and one patient remained under treatment. Conclusion Limited-stage Merkel cell carcinoma is primarily treated with surgery and radiotherapy, meanwhile, metastatic Merkel cell carcinoma needs systemic therapy, and first-line immune checkpoint inhibitors targeting PD-1/ PD-L1 pathway can achieve better therapeutic results.
